{"id":70799,"date":"2026-05-12T11:37:16","date_gmt":"2026-05-12T11:37:16","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70799"},"modified":"2026-05-13T12:36:38","modified_gmt":"2026-05-13T12:36:38","slug":"glow","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/glow\/","title":{"rendered":"GLOW Blend (BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg)"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je GLOW?<\/h3>\n

GLOW<\/strong> je kombinovan\u00e1 t\u0159\u00edpeptidov\u00e1 sm\u011bs obsahuj\u00edc\u00ed BPC-157<\/a> 10 mg, GHK-Cu<\/a> 50 mg a TB-500<\/a> 10 mg v jedn\u00e9 lyofilizovan\u00e9 lahvi\u010dce. Kombinace pokr\u00fdv\u00e1 t\u0159i dopl\u0148kov\u00e9 regenera\u010dn\u00ed mechanismy v jedn\u00e9 aplikaci: lok\u00e1ln\u00ed angiogenezi a signalizaci r\u016fstov\u00fdch faktor\u016f prost\u0159ednictv\u00edm BPC-157, m\u011b\u010f\u00ed zprost\u0159edkovanou remodelaci k\u016f\u017ee pomoc\u00ed GHK-Cu a syst\u00e9movou migraci tk\u00e1n\u00ed v\u00e1zaj\u00edc\u00ed G-aktin pomoc\u00ed TB-500. Ka\u017ed\u00e1 lahvi\u010dka obsahuje celkem 70 mg peptidu ur\u010den\u00e9ho pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00e1 sm\u011bs peptid\u016f pro v\u00fdzkumn\u00e9 \u00fa\u010dely \u00b7 HPLC \u010distota \u226599 % (ka\u017ed\u00e1 slo\u017eka, certifik\u00e1t anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Slo\u017een\u00ed<\/strong><\/td>\nBPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg v lahvi\u010dce (hmotnostn\u00ed pom\u011br 1:5:1, kombinovan\u00e9 slo\u017een\u00ed)<\/td>\n<\/tr>\n
Celkov\u00fd peptid na lahvi\u010dku<\/strong><\/td>\nCelkov\u00e1 hmotnost peptidu 70 mg<\/td>\n<\/tr>\n
\u010c\u00edsla CAS slo\u017eek<\/strong><\/td>\n137525-51-0 (BPC-157) \/ 49557-75-7 (GHK-Cu) \/ 77591-33-4 (TB-500 \/ thymosin beta-4)<\/td>\n<\/tr>\n
Profil mechanismu<\/strong><\/td>\nVEGF-zprost\u0159edkovan\u00e1 angiogeneze (BPC-157) + m\u011b\u010f\u00ed zprost\u0159edkovan\u00e1 remodelace k\u016f\u017ee (GHK-Cu) + G-aktin-v\u00e1zaj\u00edc\u00ed syst\u00e9mov\u00e1 migrace tk\u00e1n\u00ed (TB-500) \u2014 t\u0159i komplement\u00e1rn\u00ed regenera\u010dn\u00ed dr\u00e1hy<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nLyofilizovan\u00fd ko-formulovan\u00fd pr\u00e1\u0161ek (sv\u011btle modr\u00fd odst\u00edn zp\u016fsoben\u00fd v\u00e1zanou m\u011bd\u00ed)2+<\/sup>)<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599 % (ka\u017ed\u00e1 slo\u017eka ov\u011b\u0159en\u00e1 HPLC, certifik\u00e1t anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nLyofilizovan\u00e9: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00e9: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nefreeze\u2013thaw rekonstituovan\u00fd roztok.<\/td>\n<\/tr>\n
Rozpustnost<\/strong><\/td>\nBakteriostatick\u00e1 voda (doporu\u010deno). V\u0161echny t\u0159i peptidy se rekonstituuj\u00ed sou\u010dasn\u011b ze stejn\u00e9 lahvi\u010dky; rekonstituovan\u00fd roztok by m\u011bl zachovat slab\u00fd modr\u00fd odst\u00edn zp\u016fsoben\u00fd v\u00e1zanou m\u011bd\u00ed2+<\/sup> GHK-Cu.<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Co je GLOW?<\/h2>\n

GLOW<\/strong> je v\u00fdzkumn\u00fd ko-formulovan\u00fd t\u0159\u00edpeptidov\u00fd blend, kter\u00fd kombinuje BPC-157<\/a> (Slou\u010denina chr\u00e1n\u00edc\u00ed t\u011blo 157), GHK-Cu<\/a> (Glycyl-Histidyl-Lysine Copper(II) komplex), a TB-500<\/a> (Thymosin Beta-4 fragment) v jedn\u00e9 lyofilizovan\u00e9 lahvi\u010dce v hmotnostn\u00edm pom\u011bru 1:5:1 \u2014 10 mg BPC-157, 50 mg GHK-Cu a 10 mg TB-500 na lahvi\u010dku, celkem 70 mg peptidov\u00e9 hmoty. Tyto t\u0159i peptidy p\u0159edstavuj\u00ed t\u0159i z nejcitovan\u011bj\u0161\u00edch regenera\u010dn\u00edch slou\u010denin ve v\u011bdeck\u00e9 literatu\u0159e, p\u0159i\u010dem\u017e ka\u017ed\u00fd p\u016fsob\u00ed na jin\u00e9 molekul\u00e1rn\u00ed ose: BPC-157 na lok\u00e1ln\u00ed angiogenezi a signalizaci r\u016fstov\u00fdch faktor\u016f, GHK-Cu na m\u011b\u010f\u00ed zprost\u0159edkovanou remodelaci k\u016f\u017ee a antioxida\u010dn\u00ed signalizaci a TB-500 na syst\u00e9movou vazbu G-aktinu a migraci bun\u011bk.<\/p>\n

Strategick\u00e9 zd\u016fvodn\u011bn\u00ed pro blend GLOW je dopl\u0148kov\u00fdch, nep\u0159ekr\u00fdvaj\u00edc\u00edch se mechanismech<\/strong> nap\u0159\u00ed\u010d t\u0159emi regenera\u010dn\u00edmi osami. Ka\u017ed\u00fd komponentn\u00ed peptid m\u00e1 odli\u0161n\u00fd molekul\u00e1rn\u00ed c\u00edl a vzorec distribuce ve tk\u00e1n\u00edch, tak\u017ee spole\u010dn\u00e1 aplikace pokr\u00fdv\u00e1 \u0161ir\u0161\u00ed spektrum v\u00fdzkumn\u00fdch c\u00edl\u016f ne\u017e kter\u00fdkoli jednotliv\u00fd komponent s\u00e1m. Blend je ur\u010den pro v\u00fdzkum, kter\u00fd t\u011b\u017e\u00ed ze simult\u00e1nn\u00ed aktivace v\u0161ech t\u0159\u00ed drah \u2014 co\u017e je p\u0159\u00edpad odli\u0161n\u00fd od v\u00fdzkumn\u00fdch design\u016f vy\u017eaduj\u00edc\u00edch nez\u00e1visl\u00e9 d\u00e1vkov\u00e1n\u00ed ka\u017ed\u00e9ho peptidu.<\/p>\n

Pro v\u00fdzkum, kter\u00fd vy\u017eaduje nez\u00e1visl\u00e9 d\u00e1vkov\u00e1n\u00ed<\/strong> ka\u017ed\u00e9ho peptidu (r\u016fzn\u00e9 d\u00e1vky, r\u016fzn\u00e9 re\u017eimy pod\u00e1v\u00e1n\u00ed, r\u016fzn\u00e9 formy nosi\u010de), komponenty jsou tak\u00e9 dostupn\u00e9 jako samostatn\u00e9 lahvi\u010dky: BPC-157<\/a>, GHK-Cu<\/a>, a TB-500<\/a>. Samostatn\u00fd bal\u00ed\u010dek t\u0159\u00ed lahvi\u010dek \u2014 Peptidov\u00fd l\u00e9\u010debn\u00fd bal\u00ed\u010dek<\/a> (BPC-157 + TB-500 + bakteriostatick\u00e1 voda dod\u00e1van\u00e9 spole\u010dn\u011b jako t\u0159i samostatn\u00e9 lahvi\u010dky) \u2014 p\u0159edstavuje dal\u0161\u00ed alternativu pro v\u00fdzkum vy\u017eaduj\u00edc\u00ed flexibilitu d\u00e1vkov\u00e1n\u00ed jednotliv\u00fdch komponent. Formulace GLOW je ur\u010dena speci\u00e1ln\u011b pro v\u00fdzkum s pevn\u00fdm hmotnostn\u00edm pom\u011brem 1:5:1 a jednoduchou rekonstituc\u00ed z jedn\u00e9 lahvi\u010dky.<\/p>\n

GLOW je dod\u00e1v\u00e1n jako vysoce \u010dist\u00e1 lyofilizovan\u00e1 sm\u011bs pro rekonstituci bakteriostatickou vodou. Rekonstituovan\u00fd roztok si zachov\u00e1v\u00e1 slab\u00fd modr\u00fd odst\u00edn d\u00edky v\u00e1zan\u00e9 slo\u017ece GHK-Cu \u2014 co\u017e je u\u017eite\u010dn\u00fd kvalitativn\u00ed ukazatel, \u017ee koordinace m\u011bdi z\u016fstala zachov\u00e1na b\u011bhem lyofilizace a rekonstituce. GLOW nen\u00ed2+<\/sup> schv\u00e1len FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed jako kombinace nebo jako kter\u00fdkoli z jeho jednotliv\u00fdch peptid\u016f. V\u00fdzkumn\u00e1 verze GLOW prod\u00e1van\u00e1 zde je dod\u00e1v\u00e1na FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> FDA, EMA, MHRA nebo jak\u00fdmkoli jin\u00fdm v\u00fdznamn\u00fdm regula\u010dn\u00edm org\u00e1nem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed jako kombinace nebo jako kter\u00fdkoli z jeho peptidov\u00fdch slo\u017eek. V\u00fdzkumn\u00fd GLOW prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed ur\u010den pro lidsk\u00e9 ani veterin\u00e1rn\u00ed pod\u00e1v\u00e1n\u00ed.<\/p>\n

Co \u010din\u00ed formulaci GLOW farmakologicky v\u00fdjime\u010dnou, je jej\u00ed<\/h2>\n

To, co \u010din\u00ed kombinovan\u00fd p\u0159\u00edpravek GLOW farmakologicky v\u00fdjime\u010dn\u00fdm, je \u2014 ka\u017ed\u00e1 slo\u017eka aktivuje z\u00e1sadn\u011b odli\u0161nou regenera\u010dn\u00ed dr\u00e1hu a tyto t\u0159i se na molekul\u00e1rn\u00ed \u00farovni nep\u0159ekr\u00fdvaj\u00ed. Publikovan\u00fd v\u00fdzkum ka\u017ed\u00e9 slo\u017eky detailn\u011b popsal mechanismus; kombinace jednodu\u0161e dod\u00e1v\u00e1 v\u0161echny t\u0159i v jedn\u00e9 aplikaci:<\/strong> \u2014 ka\u017ed\u00e1 slo\u017eka aktivuje z\u00e1sadn\u011b odli\u0161nou regenera\u010dn\u00ed dr\u00e1hu a tyto t\u0159i se na molekul\u00e1rn\u00ed \u00farovni nep\u0159ekr\u00fdvaj\u00ed. Publikovan\u00fd v\u00fdzkum ka\u017ed\u00e9 slo\u017eky podrobn\u011b stanovil mechanismus; kombinace jednodu\u0161e dod\u00e1v\u00e1 v\u0161echny t\u0159i v jedin\u00e9m pod\u00e1n\u00ed:<\/p>\n